Novel combination therapies for the treatment of non-Hodgkin lymphoma

At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, summarizes the development of novel combination therapies for the treatment of non-Hodgkin lymphoma (NHL), including venetoclax plus bendamustine and rituximab for patients with relapsed or refractory NHL, and subcutaneous rituximab in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy for patients with previously untreated diffuse large B-cell lymphoma.

Share this video